Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
18.45
+0.01 (+0.05%)
Official Closing Price
Updated: 7:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
May 08, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
May 08, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Investor Sentiment Falls Further, Dow Gains For Fifth Session
May 08, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Uber, Lyft And 3 Stocks To Watch Heading Into Wednesday
May 08, 2024
Via
Benzinga
8 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
March 08, 2024
Via
Benzinga
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
May 06, 2024
According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation
May 03, 2024
Earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation report.
Via
Investor's Business Daily
Teva to Present at the 2024 Bank of America Healthcare Conference
May 02, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
May 02, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
May 01, 2024
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024
From
Alvotech
Via
GlobeNewswire
US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz
April 22, 2024
"Supreme Court denies review of Vanda Pharmaceuticals' patent revival attempt for Hetlioz sleep-disorder medication. Legal battle details, implications, and market impact."
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Update: Israeli Stocks On U.S. Exchanges Have Outpaced Nasdaq And S&P 500 Since October 7/23
April 17, 2024
The Israel-Hamas War has only adversely affected the stock returns of 6 of the 15 small cap Israeli- domiciled companies listed on U.S. exchanges but, In total, their returns have exceeded those of...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024
From
Alvotech
Via
GlobeNewswire
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
April 16, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
April 11, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
April 09, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Forget Nvidia: 3 Prominent Billionaire Investors Are Selling It and Buying These 6 Value Stocks Instead
April 08, 2024
Three highly successful billionaire money managers are paring down their respective stakes in artificial intelligence (AI) titan Nvidia and purchasing shares of six beaten-down value stocks.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
April 06, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
April 04, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
3 No-Brainer Stocks to Buy With $600 Right Now
April 03, 2024
A relatively modest amount of money can go a long way when it's put to work in top-tier businesses with abundant catalysts.
Via
The Motley Fool
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
April 01, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In'
March 25, 2024
Raymond James Financial, Inc. (NYSE: RJF) is now valued more highly than JPMorgan Chase & Co. (NYSE: JPM), according to Jim Cramer.
Via
Benzinga
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
March 21, 2024
GSK caps asthma and COPD medicine costs at $35/month, effective Jan 1, 2025. Includes Advair, Breo, Ventolin. Follows AstraZeneca's suit for their respiratory medicines. Sanders applauds move amid...
Via
Benzinga
The Generic Drugs Antitrust Case
March 16, 2024
Imagine that in the market for generic drugs, a group of companies form a cartel to raise prices on the products controlled by their group. What pattern might you expect to see for the prices of...
Via
Talk Markets
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
March 02, 2024
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global...
Via
Talk Markets
Drug Maker Organon Stock Scores Relative Strength Upgrade
February 28, 2024
In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday.
Via
Investor's Business Daily
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 26, 2024
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.